The Start-Up Document Set

Part of Clinical Trial Assistant (CTA) Training: Essential Documents and Start-Up.

About 4 minutes. Free, in your language, no account needed.

Why this matters

Start-up is the phase where the largest number of documents come into existence in the shortest time, under the most pressure, and where a gap has the longest consequences. A document missing at start-up is missing for every participant enrolled afterwards.

What must exist before a site screens anyone

The list varies by jurisdiction, but the logic does not. Before the first participant is screened, the file should hold:

• The protocol and any amendments in force, signed by the investigator.
• The current investigator's brochure, and evidence the site received it.
• Written approval or favorable opinion from the ethics committee, naming the documents and versions approved, and evidence of the committee's composition or a statement of its constitution.
• Regulatory authorization where the jurisdiction requires one before start.
• The consent form version approved for use, in every language the site will consent in.
• Signed agreements: the clinical trial agreement and the financial agreement.
• Current signed CVs and evidence of qualification for everyone on the delegation log.
• The delegation log itself, signed and dated before anyone performs a delegated task.
• Laboratory certification or accreditation and current reference ranges.
• Evidence of adequate facilities, and of investigational product handling arrangements.

If you can only remember one test: does the file show that an approved protocol, an approved consent form and a qualified delegated team were all in place on the day screening started.

Jurisdictions differ, and the difference is the point

E6(R3) states the requirement; national law states the mechanism. A site in the European Union works under Regulation (EU) 536/2014 with a single submission through the Clinical Trials Information System. A site in India works under the New Drugs and Clinical Trials Rules, 2019. A site in South Africa works under the Medicines and Related Substances Act and the South African GCP guidelines, where compliance is compulsory rather than advisory.

Never assume the pack that worked at your last site is the pack this site needs. Ask what the national instrument requires, and file the evidence that it was satisfied.

Sequencing is a competency, not an administrative detail

Documents have dependencies. The ethics committee approves specific versions, so the versions must exist first. The delegation log must precede the delegated work. The product cannot ship before the site is authorized to receive it.

A start-up plan that lists documents without their dependencies will produce a file that is complete and still wrong, because things happened in the wrong order and the dates will show it.

In practice

A study is opening three sites: one in Germany, one in India, one in South Africa. The start-up pack that worked in Germany is sent to all three.

It does not work. Germany operates under Regulation (EU) 536/2014 with submission through the Clinical Trials Information System and a coordinated assessment across member states. India works under the New Drugs and Clinical Trials Rules, 2019, with its own submission route and its own ethics committee registration requirements. South Africa works under the Medicines and Related Substances Act with the South African GCP guidelines, where compliance is compulsory rather than advisory, and with its own national health research ethics structure.

The common core is real: approved protocol, approved consent, qualified delegated team, capable site. The route to evidencing each differs, and assuming otherwise costs weeks at exactly the point in the study where weeks are most expensive.

The question to ask at every new country

Ask the local regulatory contact three things before building the pack.

Which approvals are required before screening may begin, and in what order? In some jurisdictions ethics precedes regulatory, in others the reverse, and in some they run in parallel with the second depending on the first.

What must be submitted in the local language, and does it need certified translation? This is on the critical path more often than anything else.

What does the local instrument require that ICH does not? This is where surprises live: additional insurance requirements, site registration, importation licensing, local legal representation.

Write the answers down per country. You will run the same study in the same countries again.

Key takeaways

• A gap at start-up is a gap for every participant enrolled afterwards.
• The test: approved protocol, approved consent form, qualified delegated team, all in place on the day screening began.
• The requirement is common; the mechanism is national. Ask what the local instrument demands.
• Sequencing matters as much as presence, and dates will reveal it.